161 related articles for article (PubMed ID: 22030088)
1. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.
Chan AT; Hsu M; Zauber AG; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2012 Jan; 5(1):61-72. PubMed ID: 22030088
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
Chan AT; Sima CS; Zauber AG; Ridker PM; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1172-80. PubMed ID: 21816845
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
Chan AT; Zauber AG; Hsu M; Breazna A; Hunter DJ; Rosenstein RB; Eagle CJ; Hawk ET; Bertagnolli MM
Gastroenterology; 2009 Jun; 136(7):2127-2136.e1. PubMed ID: 19233181
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
Hubner RA; Muir KR; Liu JF; Logan RF; Grainge M; Armitage N; Shepherd V; Popat S; Houlston RS;
Clin Cancer Res; 2006 Nov; 12(21):6585-9. PubMed ID: 17085674
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
Chan AT; Tranah GJ; Giovannucci EL; Hunter DJ; Fuchs CS
J Natl Cancer Inst; 2005 Mar; 97(6):457-60. PubMed ID: 15770010
[TBL] [Abstract][Full Text] [Related]
8. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
9. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Breazna A; Kim K; Tang J; Rosenstein RB; Umar A; Bagheri D; Collins NT; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Hawk ET;
Cancer Prev Res (Phila); 2009 Apr; 2(4):310-21. PubMed ID: 19336730
[TBL] [Abstract][Full Text] [Related]
10. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.
Thompson P; Roe DJ; Fales L; Buckmeier J; Wang F; Hamilton SR; Bhattacharyya A; Green S; Hsu CH; Chow HH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Martinez ME; Jacobs E; Ashbeck EL; Alberts DS; Lance P
Cancer Prev Res (Phila); 2012 Dec; 5(12):1381-93. PubMed ID: 23060037
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
12. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165
[TBL] [Abstract][Full Text] [Related]
13. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.
Bertagnolli MM; Hsu M; Hawk ET; Eagle CJ; Zauber AG;
Cancer Prev Res (Phila); 2010 May; 3(5):588-96. PubMed ID: 20403998
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.
Thompson PA; Ashbeck EL; Roe DJ; Fales L; Buckmeier J; Wang F; Bhattacharyya A; Hsu CH; Chow SH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Hamilton SR; Jacobs ET; Martinez EM; Alberts DS; Lance P
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27530656
[TBL] [Abstract][Full Text] [Related]
15. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
Kraus S; Hummler S; Toriola AT; Poole EM; Scherer D; Kotzmann J; Makar KW; Kazanov D; Galazan L; Naumov I; Coghill AE; Duggan D; Gigic B; Arber N; Ulrich CM
Pharmacogenet Genomics; 2013 Aug; 23(8):428-437. PubMed ID: 23778325
[TBL] [Abstract][Full Text] [Related]
16. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Rahme E; Barkun AN; Toubouti Y; Bardou M
Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
[TBL] [Abstract][Full Text] [Related]
17. Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.
Veettil SK; Lim KG; Ching SM; Saokaew S; Phisalprapa P; Chaiyakunapruk N
BMC Cancer; 2017 Nov; 17(1):763. PubMed ID: 29137605
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Bigler J; Whitton J; Lampe JW; Fosdick L; Bostick RM; Potter JD
Cancer Res; 2001 May; 61(9):3566-9. PubMed ID: 11325819
[TBL] [Abstract][Full Text] [Related]
19. Aberrant crypt foci in the adenoma prevention with celecoxib trial.
Cho NL; Redston M; Zauber AG; Carothers AM; Hornick J; Wilton A; Sontag S; Nishioka N; Giardiello FM; Saltzman JR; Gostout C; Eagle CJ; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2008 Jun; 1(1):21-31. PubMed ID: 19138933
[TBL] [Abstract][Full Text] [Related]
20. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]